**The 2018 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation**

***Executive Summary***

Jan Steffel1, Peter Verhamme2, Tatjana S. Potpara3, Pierre Albaladejo4, Matthias Antz5,
Lien Desteghe6, Karl Georg Haeusler7, Jonas Oldgren8, Holger Reinecke9, Vanessa Roldan-Schilling10, Nigel Rowell11, Peter Sinnaeve12, Ronan Collins13, A. John Camm14, and
Hein Heidbüchel15

1 University Heart Center Zurich, Zurich, Switzerland

2 Centre for Molecular and Vascular Biology, University of Leuven, Belgium

3 School of Medicine, Belgrade University, Belgrade, Serbia

4 University Hospital Grenoble, Grenoble, France

5 City Hospital Braunschweig, Braunschweig, Germany

6 Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium

7 Center for Stroke Research Berlin and Department of Neurology, Charité - Universitätsmedizin Berlin

8 Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden

9 University Hospital Münster, Münster, Germany

10 University of Murcia, Murcia, Spain

11 Endeavour Practice, Middlesbrough, UK

12 Department of Cardiovascular Sciences, University of Leuven, Belgium

13 Director of Stroke Services, Tallaght Hospital, Dublin, Ireland

14 Cardiology Clinical Academic Group, Molecular & Clinical Sciences Institute, St George’s University, London, UK

15 Antwerp University and University Hospital, Antwerp, Belgium

Address for correspondence:

Jan Steffel, MD FESC FEHRA FHRS

Department of Cardiology, University Heart Center Zurich

Rämistrasse 100

CH-8091 Zurich / Switzerland

Tel.: +41 44 255 15 15

E-Mail: j.steffel@gmx.ch

**Advisors:** Martin van Eikels, M.D. (Bayer Healthcare), Jutta Heinrich-Nols, M.D. (Boehringer Ingelheim), Markus Müller, M.D., Ph.D. (Pfizer), Wolfgang Zierhut, M.D. (Daiichi-Sankyo), and Poushali Mukherjea, PhD (Bristol-Myers Squibb)

**Document reviewers:** …

**Abstract**

The current manuscript is the Executive Summary of the second update to the original Practical Guide, published in 2013.[1](#_ENREF_1), [2](#_ENREF_2) Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF), and have emerged as the preferred choice, particularly in patients newly started on anticoagulation. Both physicians and patients are becoming more accustomed to the safe and effective use of these drugs in clinical practice. However, many unresolved questions on how to optimally use these agents in specific clinical situations remain. The European Heart Rhythm Association (EHRA) set out to coordinate a unified way of informing physicians on the use of the different NOACs. A writing group identified 20 topics of concrete clinical scenarios for which practical answers were formulated, based on available evidence. The 20 topics are (1) Eligibility for NOACs; (2) Practical start-up and follow-up scheme for patients on NOACs; (3) Ensuring adherence to prescribed oral anticoagulant intake; (4) Switching between anticoagulant regimens; (5) Pharmacokinetics and drug-drug interactions of NOACs; (6) NOACs in patients with chronic kidney or advanced liver disease; (7) How to measure the anticoagulant effect of NOACs; (8) Plasma NOAC level measurement: rare indications, precautions and potential pitfalls; (9) How to deal with dosing errors; (10) What to do if there is a (suspected) overdose without bleeding, or a clotting test is indicating a potential risk of bleeding?; (11) Management of bleeding under NOAC therapy; (12) Patients undergoing a planned invasive procedure, surgery or ablation; (13) Patients requiring an urgent surgical intervention; (14) Patients with AF and coronary artery disease; (15) Avoiding confusion with NOAC dosing across indications; (16) Cardioversion in a NOAC-treated patient; (17) AF patients presenting with acute stroke while on NOACs; (18) NOACs in special situations; (19) Anticoagulation in AF patients with a malignancy; and (20) Optimizing dose adjustments of VKA. Additional information and downloads of the text and anticoagulation cards in different languages can be found on a European Heart Rhythm Association web site (www.NOACforAF.eu).

**Introduction**

The proper use of non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation (AF) requires a diligent approach in various settings of daily clinical practice.[2](#_ENREF_2) This Practical Guide, as its predecessors from 2013 and 2015, supplements the Guidelines, providing guidance on how to use NOACs in specific clinical situations.[1-3](#_ENREF_1) The main pointers of the 2018 version of the European Heart Rhythm Association (EHRA) Practical Guide are summarized in this Executive Summary. The full text of the Update is published in the European Heart Journal.[INSERT REFERENCEC HERE] The 2018 EHRA Practical Guide will also be presented in an new version of the slide kit (downloadable for free by EHRA members) and a Key Message booklet, which can be obtained through EHRA and ESC. The reader is referred to visit www. NOACforAF.eu Web site for up-to-date information, where also feedback can be provided.

**Eligibility for NOACs**

Strictly, the term “non-valvular AF” refers to AF in the absence of a mechanical prosthetic heart valve or moderate to severe mitral stenosis (usually of rheumatic origin).[4-8](#_ENREF_4) The term “non-valvular” has been eliminated in the 2016 ESC guidelines on the management of patients with AF and is also not used anymore in this practical guide.[4](#_ENREF_4), [6](#_ENREF_6) Indeed, all other native valvular stenosis and insufficiencies as well as a moderately sized group of patients after mitral valve repair and bioprosthetic valve replacements were included in the pivotal NOAC trials in which they demonstrated a comparable relative efficacy and safety vs. warfarin in patients with vs. without valvular disease (except for a higher risk of bleeding with rivaroxaban vs. warfarin in patients with valvular heart disease in a post-hoc analysis of the ROCKET-AF trial).[6](#_ENREF_6), [9-14](#_ENREF_9) NOACs may therefore be used in such patients.[4](#_ENREF_4), [6](#_ENREF_6), [15](#_ENREF_15) One exception may be AF in the presence of a biological mitral prosthesis implanted for rheumatic mitral stenosis. Although mitral valve flow is normalized post mitral valve replacement in these patients, their atria usually remain large and severely diseased. As such, VKA may be the preferred option over NOACs in these patients, but more data are needed. In hypertrophic (obstructive) cardiomyopathy there is limited experience with NOACs in this condition but from a pathophysiological perspective NOACs can be used in these patients.[16](#_ENREF_16), [17](#_ENREF_17)

**Practical start-up and follow-up scheme for patients on NOACs**

With four NOACs available in different dosages for different indications and with different dose reduction criteria, identification of the correct dose has become more complicated and is one of the key challenges in the daily use and individualization of treatment.[18-22](#_ENREF_18) **Dose reduction of NOACs is primarily recommended according to the published dose reduction criteria. Whenever possible, the tested standard dose of NOACs should be used to provide optimal benefit for the patient.** Also patient age, weight, renal function, co-medications and other comorbidities influence the choice.

Bleeding risk can be assessed using the HAS-BLED score. Importantly, however, a high score in itself should not automatically result in decision not to anticoagulate as stroke risk tracks along with the HAS-BLED score.[4](#_ENREF_4), [23](#_ENREF_23) Minimizing modifiable risk factors is of critical importance in order to minimize the risk of bleeding, and HAS-BLED can help to do that in a systematic fashion.[4](#_ENREF_4)

The proposed NOAC card (Figure 1) presented in this version of the Practical Guide has been updated and will be available for download in various languages at www.NOACforAF.eu. Critical elements in the follow-up of patients (and in the assurance of optimal adherence) are summarized in figure 2.

**Importance of drug-drug interactions of NOACs**

Despite fewer interactions with NOACs compared to VKA, physicians need to consider the pharmacokinetic interactions of accompanying drugs and comorbidities when prescribing NOACs.[2](#_ENREF_2) The use of plasma level monitoring for NOAC dose-adjustment is discouraged for the vast majority of patients due to the lack of outcome data to support such an approach. Only in very rare cases of potentially substantial drug-drug interactions or special situations in which a certain NOAC is preferred for certain reasons (e.g., patients after transplantation, patients on HIV medication etc.) this may be considered. Importantly, this approach should be limited to centres with extensive experience in the performance and interpretation of such assays as well as in the care of NOAC-treated patients.

**NOACs in patients with chronic kidney disease or advanced liver disease**

In the context of NOAC treatment, renal function should preferably be estimated by calculating the creatinine clearance (CrCl) using the Cockcroft–Gault method, which was used in most NOAC trials. In patients on NOACs, renal function needs to be monitored diligently, at least yearly, to detect changes in renal function and adapt the dose accordingly. If renal function is impaired (i.e. CrCl ≤ 60 ml/min), a more frequent evaluation is recommended (e.g., by dividing CrCl by 10 to obtain the minimum frequency of renal function testing in months).

Compared with warfarin, all four NOACs showed consistent efficacy and safety in patients with **mild to moderate** CKD compared with non-CKD patients in the respective sub-group analyses of pivotal NOAC trials.[24-29](#_ENREF_24) In addition, the ARISTOTLE trial data analysis suggests that the bleeding benefit with apixaban compared to warfarin becomes significantly more prominent at lower CrCl values, while the stroke reduction benefit is maintained.[26](#_ENREF_26), [30](#_ENREF_30) In contrast, the bleeding benefit of 110 mg dabigatran over warfarin is lost in patients with CrCl < 50 ml/min while maintaining a similar stroke risk reduction compared to VKA.[24](#_ENREF_24)

There are no randomized clinical trial (RCT) data on the use of NOACs or warfarin for stroke prevention in AF patients with **severe CKD** or on **renal replacement therapy** (RRT). The efficacy and safety of NOACs in patients with end-stage renal dysfunction and on dialysis is unclear and subject to ongoing studies. (e.g. NCT02942407, NCT02933697). Given the lack of strong evidence also for VKA in this patient population, the decision to anticoagulate remains a very individualized one requiring a multidisciplinary approach considering and respecting patients’ preferences.[31-33](#_ENREF_31)

The use of VKAs in patients with **advanced liver disease** and coagulopathy is challenging due to intrinsically elevated INR values and difficulties in selecting appropriate VKA dosing.[34-38](#_ENREF_34) Also all four NOACs are contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk including Child-Turcote-Pugh C cirrhosis. Rivaroxaban should also not be used in AF patients with Child B liver cirrhosis.[39](#_ENREF_39)

**How and when to measure the anticoagulant effect of NOACs?**

NOACs do not require monitoring of coagulation. However, laboratory assessment of drug exposure and anticoagulant effect may help clinicians in emergencies such as bleeding, urgent procedures, suspected overdose or acute stroke. In can also be considered to guide long-term treatment in exceptional patients with special characteristics. This, however, should only be done under the guidance of a coagulation expert and in the knowledge that hard clinical outcome data do not exist for such a strategy.

Routine coagulation tests (PT and aPTT) generally do not provide an accurate assessment of NOAC anticoagulant effects. However, the latter can be measured via specific coagulation assays developed for the quantification of NOAC plasma levels.[40-42](#_ENREF_40) The use of appropriate calibrators allows for the determination of plasma concentrations of all NOACs. It is recommended that lab should be experienced with these measurements. Moreover, emergency situations will require 24/7 availability of the specific assays, which is currently only possible in a minority of labs.

**Management of bleeding under NOAC therapy**

Strategies to manage bleeding complications in patients treated with NOACs rely on a precise analysis of the clinical situation.

1) The type of bleeding: nuisance / minor, major non-life threatening, or life-threatening.

2) The patient and his / her treatment, including the exact time of last NOAC intake, prescribed dosing regimen, renal function, other factors influencing plasma concentrations, and other factors influencing haemostasis (such as concomitant use of antiplatelet drugs).

Depending on the clinical scenario, the anticoagulant effects in a NOAC-treated patient who presents with bleeding can be addressed with the following strategies:

1) **Waiting** until the anticoagulant activity of the NOAC effect wanes as a result of spontaneous clearance of the drug

2) **Specific reversal**. A specific reversal agent is available for dabigatran (idarucizumab, a humanized antibody fragment that specifically binds dabigatran).[43](#_ENREF_43) Specific agents for FXa inhibitors are undergoing clinical testing, including andexanet alfa[44](#_ENREF_44) and ciraparantag (PER 977).[45](#_ENREF_45)

**3) Non-specific support of haemostasis** using coagulation factors concentrates. There is increasing information about the effects of (activated) prothrombin complex concentrates in cohorts of NOAC-treated patients with bleeding.[46](#_ENREF_46) In contrast, the use of fresh frozen plasma is not considered a useful reversal strategy.[47](#_ENREF_47) The use of antifibrinolytics (e.g. tranexamic acid, 1g i.v., repeated every 6 hours if needed) or desmopressin 0.3 µg/kg i.v. infusion (with a maximal dosing of 20 µg) - especially in special situations with associated coagulopathy or thrombopathy – may be considered.

**Nuisance bleeds** can usually be managed by delaying intake or withholding the NOAC for a maximum of one dose. **Minor bleedings** may require more aggressive therapy with a focus aimed at treating the cause of the bleeding (e.g. PPI for gastric ulcers, antibiotics for urinary tract infection, etc.). Epistaxis and gum bleeds can be treated with local anti-fibrinolytics. In case of recurrent minor bleeding events without causal therapeutic options, an alternative NOAC with a potentially different bleeding profile should be considered while maintaining effective stroke prevention. A suspected or documented occult bleeding should trigger a work-up to uncover the underlying cause and the treatment thereof whenever possible. Cessation or temporary interruption without consultation needs to be discouraged due to the subsequently increased thromboembolic risk. **Major and / or life-threatening bleeding** needs to be aggressively managed including the use of specific as well as non-specific reversal strategies.

**Patients undergoing a planned invasive procedure, surgery or ablation**

Awaiting the results of the ongoing Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE; NCT02228798), few prospective data on the management of NOACs are available.[48](#_ENREF_48)

It is recommended not to interrupt oral anticoagulation for most **minor surgical** procedures and those procedures where bleeding is easily controllable. In general, these procedures can be performed 12 to 24 hours after the last NOAC intake, with NOAC restart 6 hours later.

For invasive procedures with a **low bleeding risk** (including cardiac device implantations), it is recommended to take the last dose of a NOAC 24 hours or more before the elective procedure in patients with normal kidney function.[49](#_ENREF_49) For patients on dabigatran and a CrCl <80 ml/min a graded interruption should be considered.

In case of invasive procedures that carry a **high risk for major bleeding**, it is recommended to take the last NOAC dose 48 hours or longer before surgery. In cases with combined factors that make prediction of NOAC clearance unclear, measurement of NOAC plasma levels may be considered, and only go ahead with the planned surgical intervention when the level is considered low enough. However, such an approach is without evidence base, including the determination of ‘safe’ NOAC levels in this setting as well as waiting for levels to drop into that range whilst accepting the inherent risk of thromboembolism during that time.

Preoperative bridging with LMWH or heparin is not recommended in NOAC-treated patients.

**After** **a procedure** with immediate and complete haemostasis, NOACs can generally be resumed 6 – 8 h after the end of the intervention. In surgical interventions for which resuming full dose anticoagulation within the first 48 – 72 h after the procedure carries a bleeding risk that may outweigh the risk of AF-related embolism, postoperative thromboprophylaxis 6 – 8 h after surgery and delay of therapeutic anticoagulation by restarting the NOAC to >48 – 72 h can be considered.

Whether opting to administer the last NOAC dose shortly before an **AF ablation procedure** (i.e. ‘truly uninterrupted’) or to go for a short cessation period (last NOAC dose on the day before the procedure), may depend on a number of factors (Figure 3).[2](#_ENREF_2), [50-55](#_ENREF_50) It is reasonable to administer a last dose of NOAC 12 h before the start of the intervention, especially if transseptal puncture is performed without periprocedural imaging (as is mostly the case in Europe).[50](#_ENREF_50)

**Patients requiring an urgent surgical intervention**

If an emergency intervention is required, the NOAC should be discontinued immediately. Specific management will then depend on the level or urgency.[56](#_ENREF_56)

**Immediate procedures** (Immediate life-, limb- or organ-saving intervention, typically cardiac, vascular, neurosurgical emergency procedures) need to be performed within minutes of the decision to operate and cannot be delayed. In these cases, reversal with idarucizumab (for dabigatran)[43](#_ENREF_43) should be considered, especially in moderate- to high haemorrhagic risk procedures.[57](#_ENREF_57) If specific reversal agents are not available, PCCs or aPCCs should be considered despite the clinical lack of evidence for efficacy and safety (only animal data).[58-60](#_ENREF_58)

**Urgent procedures** (e.g., intervention for acute onset or clinical deterioration of potentially life-threatening conditions, conditions that may threaten the survival of limb or organ, fixation of fractures, relief of pain or other distressing symptoms) need to be performed within hours of the decision to operate. In these situations, surgery or intervention should be deferred, if possible, until at least 12 h and ideally 24 h after the last dose. Also, coagulation test results (see below) can be awaited in this situation to gauge the necessity for reversal or application of (a)PCCs.

**Expedite procedures** (patients requiring early treatment where the condition is not an immediate threat to life, limb or organ survival) should be performed within days of decision to operate. In these situations, interruption of NOACs should follow the proposed rules for elective surgery.

**Patient with AF and coronary artery disease**

The combination of AF and CAD not only is a common and complex clinical setting to deal with regarding anticoagulation and antiplatelet therapy, it is also associated with significantly higher morbidity and mortality.[61](#_ENREF_61), [62](#_ENREF_62) The practice of adding aspirin or a P2Y12 inhibitor to a (N)OAC is referred to as ‘dual therapy’, while adding both aspirin and a P2Y12 inhibitor to a (N)OAC is called ‘triple therapy’. Dual antiplatelet therapy is referred to as ‘DAPT’.

A meta-analysis combining WOEST, PIONEER AF-PCI and RE-DUAL PCI suggests that the likelihood of an excess of thromboembolic events during dual therapy vs. triple therapy is low.[63](#_ENREF_63) Two ongoing trials, AUGUSTUS (NCT02415400) and ENTRUST-AF PCI (NCT02866175)[64](#_ENREF_64) will add further information on how and how long (if at all) triple anticoagulation should be administered.

In general the bleeding risk seems to be lower with a NOAC plus antiplatelet combination than with a VKA plus antiplatelet combination.[65-67](#_ENREF_65) The length of DAPT / triple therapy no longer depends on the type of stent (i.e., DES or BMS) but on the clinical presentation of the patient.[4](#_ENREF_4), [68](#_ENREF_68) Today, the “default” duration of triple therapy may be as short as 3 month after ACS and 1 month after elective stenting; however, both the duration of aspirin and / or P2Y12 inhibitor as well as the choice of NOAC need to be individualized, based on a careful assessment of ischaemic- versus bleeding risk. In the setting of dual therapy it may be feasible to use one of the newer P2Y12 inhibitors with a (N)OAC under certain circumstances such as perceived high thrombotic risk, ACS, or prior stent thrombosis.

The 2017 ESC DAPT and 2016 AF guidelines recommend discontinuing any antiplatelet agent at 12 months after a PCI or ACS episode (see following paragraphs) and to only consider keeping one antiplatelet plus a (N)OAC beyond 12 months in patients at very high risk of coronary events.[4](#_ENREF_4), [68](#_ENREF_68)

**Cardioversion in a NOAC treated patient**

Based on current ESC guidelines,[4](#_ENREF_4) in patients with AF of ≥ 48 h (or unknown) duration undergoing electrical or pharmacological cardioversion, effective oral anticoagulation needs to be established for at least 3 weeks prior to cardioversion or transesophageal echocardiography (TOE) performed to rule out left atrial thrombi. After cardioversion, continuous oral anticoagulation is mandatory for at least another 4 weeks, irrespective of CHA2DS2-VASc score.[4](#_ENREF_4), [69](#_ENREF_69)

A strategy with at least a single NOAC dose ≥4 h before cardioversion (≥ 2h after apixaban loading dose) appears safe and effective in patients with AF of ≥ 48 h duration, provided that a TOE is performed prior to cardioversion. The alternative is starting anticoagulation with a NOAC first, and delaying cardioversion for at least 3 weeks.[70-74](#_ENREF_70) A similar strategy of starting the NOAC before cardioversion, with a TOE dependent on institutional policy or patient elevated stroke risk, is applicable to those with AF of <48h duration.

Patients in whom TOE identifies a left atrial thrombus should not undergo cardioversion. Treatment with VKA is standard in these situations but NOACs may also be an option, particularly in patients where a VKA is not well tolerated or adequate INR control cannot be obtained.

**AF patients presenting with acute stroke while on NOAC**

Thrombolytic therapy cannot be given (according to its label) within 24 hours after the last intake of a NOAC due to their plasma half-lives. The case is different for dabigatran due to the availability of the rapid acting specific reversal agent, idarucizumab. After reversal and assessment of coagulation status, intravenous thrombolysis within 4.5 hours of onset of moderate to severe stroke seems feasible and safe.[75-77](#_ENREF_75) Based on expert consensus, the use of rt-PA may be considered in selected patients on a NOAC in cases in which a reliable and NOAC specific coagulation assessment is available without long delay and demonstrating a concentration < 30 ng/ml for rivaroxaban, apixaban or edoxaban.[78-80](#_ENREF_78)

There is a proven benefit of endovascular thrombectomy up to 7.3 hours after stroke onset in selected non-anticoagulated patients with a distal occlusion of the internal carotid artery or the proximal middle cerebral artery,[81](#_ENREF_81) and thrombectomy also seems to be beneficial in highly selected stroke patients within 6 to up to 24 hours of last seen normal.[82](#_ENREF_82), [83](#_ENREF_83) Endovascular thrombectomy Is now mentioned as “first-line treatment” in patients with contraindication for intravenous thrombolysis, while the AHA’s guidelines provide no specific recommendation in this regard.[84](#_ENREF_84), [85](#_ENREF_85) Although the trials underlying these recommendations either excluded or contained just a few patients on VKA or NOAC, the small amount of data available suggests that endovascular thrombectomy may be safe also in these individuals.

In AF patients after ischaemic stroke, NOACs should be (re-) initiated in analogy to clinical practice with VKAs. Recommendations on (re-) starting of oral anticoagulation after ischaemic stroke must outweigh (recurrent) stroke risk vs. secondary haemorrhagic transformation.[4](#_ENREF_4), [86-88](#_ENREF_86)

In analogy to patients with **acute intracranial bleeding (ICB)** being treated with warfarin, discontinuation of the drug, urgent blood pressure management and rapid correction of the coagulation status (ideally with a direct reversal agent) is needed to limit haematoma enlargement in patients under NOAC.[89-91](#_ENREF_89)

In the absence of randomised controlled trials, a case-by-case consideration is needed whether or not to reintroduce anticoagulation of any type in patients who have experienced an anticoagulation-related ICB.[4](#_ENREF_4), [91-93](#_ENREF_91) Left atrial appendage occlusion may be considered, but also here randomized evidence is missing, which is why, ideally, treatment should occur in the framework of a randomized trial to contribute to evidence.[94](#_ENREF_94)

**NOACs in special situations**

Meta-analyses of NOAC trial data suggest no interaction of **age** for safety and efficacy (except for an increased extracranial major bleeding with the 150 mg BID dose of dabigatran).[95](#_ENREF_95), [96](#_ENREF_96) Importantly the higher absolute stroke risk resulted in a larger absolute risk reduction by using NOACs instead of VKA in these older patients, resulting in a lower number needed to treat compared to younger patients (see table 1).[97](#_ENREF_97)

**Falls** and risk of subdural haemorrhage in particular are often considered by physicians as a contraindication to OAC.[98](#_ENREF_98), [99](#_ENREF_99) However, frailty and a (perceived) increased risk of falling per se should not be an exclusion criterion to anticoagulate since frail and older patients are at an increased risk of stroke and have been shown to benefit from NOAC therapy (best shown for edoxaban and apixaban).[100-102](#_ENREF_100) [103-105](#_ENREF_103)

**Dementia** should not be a viewed as a general contraindication to anticoagulation either, especially if well managed from a logistical point of view. Paradoxically, the fact that others take care of providing medication to dementia patients may guarantee higher adherence.

Overall, NOACs appear to be similarly safe and effective in patients with **moderate obesity** (up to 120 kg) or **moderate underweight** (down to 50 kg).[38](#_ENREF_38), [106-120](#_ENREF_106) For patients with low body weight (< 60 kg) specific dose reduction criteria were employed in the trials for edoxaban and apixaban possibly making those drugs the preferred choice in these patients. Because of limited data in extremes of body weight, the use of VKA in patients with a BMI > 40Kg/m2 (or weight > 120 kg) as well as in those weighting < 50kg should be considered (in line with recommendations from the International Society on Thrombosis and Haemostasis).[113](#_ENREF_113) In rare case when a NOAC is needed in such circumstances, specific measurements of drug trough levels should be considered. This, however, should only be done under the guidance of a haematologist and in the knowledge that hard clinical outcome data do not exist for such an approach.

All OAC use should be considered with caution in **women of childbearing age** and an appropriate test to rule out pregnancy and contraceptive counselling advice arranged before initiation of any agent. Abnormal uterine bleeding (AUB; formerly called *menorrhagia),* occurs in 9-14 % of the general female population of a reproductive age,[121](#_ENREF_121) which may be exacerbated by oral anticoagulants.[122](#_ENREF_122) All cases of AUB on OAC need to have gynaecological assessment. Importantly, NOACs are contraindicated in pregnancy as well as during breastfeeding.

In patients with **epilepsy**, anticoagulation is affected by antiepileptic drugs via various potential interactions.[123](#_ENREF_123) The significance of these drug-drug interactions is still largely unknown with only occasional case reports available.

**Anticoagulation in atrial fibrillation patients with a malignancy**

So far, the only published randomized clinical trial specifically targeting cancer patients stems from the HOKUSAI-VTE Cancer trial comparing edoxaban with LMWH in patients with VTE (but not AF).[124](#_ENREF_124) In line with these findings, several meta-analyses of the small subgroup of cancer patients in VTE trials reported similar or better efficacy of NOACs in comparison to VKA or LMWH for VTE prevention, although major bleeding rates were higher.[125](#_ENREF_125), [126](#_ENREF_126) In how far these findings apply to AF patients with cancer requires further data. Indeed, much is still unknown about drug-drug interactions between NOACs and specific chemotherapeutic agents, urging further caution.[127](#_ENREF_127)

**Optimizing dose adjustments of Vitamin-K Antagonists**

Automated dosing calculators are available that help in the determination of the ‘optimal’ starting regimen for VKA (e.g., http://www.warfarindosing.org). During maintenance therapy, using dosing algorithms to optimize VKA dosing and, ultimately, the time in therapeutic range (TTR) has been shown to be useful.[128-130](#_ENREF_128) Importantly from a conceptual point of view, dosing is optimized not using daily dose adjustments but adjustments based on the weekly intake in warfarin. Receiving care at a dedicated anticoagulation clinic[131](#_ENREF_131), [132](#_ENREF_132) as well as self-monitoring and self-management[133](#_ENREF_133) has been shown to improve INR control in well selected patients.

**Figure Legends**

**Figure 1: The EHRA NOAC card**

A patient information card is crucial, both for the patient (instructions on correct intake; contact information in case of questions) as for healthcare workers (other caretakers are involved; renal function; follow-up schedule; concomitant medication, etc.). This generic and universal card can serve all patients under NOAC therapy.

**Figure 2: Selection of possibilities to increase adherence to NOACs**

NB: These icons are from the web and need to be redrawn by the publisher prior to publication

**Figure 3: NOAC management before and after atrial fibrillation ablation**

TSP – transseptal puncture; LA – left atrium; LAA – left atrial appendage

**Table 1: Summary of age profile and interaction of age on bleeding in NOAC trials**

|  |  |  |  |
| --- | --- | --- | --- |
| Trial | >75 group(overall % /numbers) |  **Major bleeding** %/pt years NOAC vs VKA per age group – P interaction by age  | **Intracranial bleeding**%/pt yrs NOAC vs VKA per age group – P interaction by age |
| **RE-LY*** Dabigatran 110 mg BID
* Dabigatran 150 mg BID
 | 41% (n*= 7258)* | * 4.43% vs. 4.37% >75
* 1.89% vs 3.04% < 75

 **P for interaction <0.001*** 5.10% vs 4.37% >75
* 2.12% vs 3.04% <75

 **P for interaction <0.001** |  * 0.37% vs 1.00% >75
* 0.14% vs 0.61% < 75

P for interaction = 0.28* 0.41% vs 1.0% > 75
* 0.26% vs 0.61% <75

P for interaction =0.91 |
| **ROCKET-AF*** Rivaroxaban 20 mg OD

(per protocol dose reduction to 15 mg in 20%) | 44% (n= 6229) | * 4.86% vs 4.40% >75
* 2.69% vs 2.79 % <75

  P for interaction =0.336 | * 0.34 % vs 0.49 % >75
* 0.20% vs 0.41% <75

P for interaction =0.365 |
| **ARISTOTLE**Apixaban 5 mg BID(per protocol dose reduction to 2.5 mg BID in 4.7%) | *31% (*n*= 5678)* | * 3.3% vs 5.2% > 75
* 2.0% vs 2.8% 65-<75
* 1.17% vs 1.51% < 65

 P for interaction = 0.63(continuous ) | * 0.43 vs% 1.29% >75
* 0.28% vs 0.81% 65- 75
* 0.31% vs 0.35% <65

P for interaction = 0.20(continuous ) |
| **ENGAGE-AF TIMI 48** Higher dose edoxaban regimen * Edoxaban 60 mg OD

(28.6 % < 75 and 41% > 75 dose reduced to 30 mg)Lower dose edoxaban regimen\** Edoxaban 30 mg OD

(28.6 % < 75 and 41% > 75 dose reduced to 15 mg)\*not licensed  | 40% (n=8474) | * 4.0% vs 4.8% >75
* 2.0% vs 2.6% <75

P for interaction = 0.57* 2.3% vs 4.8% >75
* 1.2% vs 2.6% <75

P for interaction = 0.95 | * 0.5% vs 1.2% > 75
* 0.3% vs 0.6% <75

P for interaction =0.34* 0.4% vs 1.2% > 75
* 0.2% vs 0.6% <75

P for interaction =0.99 |

**Conflict of Interest Disclosures**

Dr. Steffel has received consultant and / or speaker fees from Amgen, Astra-Zeneca, Atricure, Bayer, Biosense Webster, Biotronik, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cook Medical, Daiichi Sankyo, Medtronic, Novartis, Pfizer, Sanofi-Aventis, Sorin, St. Jude Medical / Abbott and Zoll. He reports ownership of CorXL. Dr. Steffel has received grant support through his institution from Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, Daiichi Sankyo, Medtronic, und St. Jude Medical / Abbott.

Dr. Verhamme reports grants and personal fees from Bayer, Boehringer Ingelheim, BMS, Leo Pharma, Daiichi-Sankyo; and personal fees from Pfizer, Medtronic, and Portola.

Dr. Potpara has received speaker fees from Pfizer and Bayer.

Dr. Albaladejo reports personal fees from Boehringer Ingelheim, personal fees and non-financial support from Bayer and Portola, and grants, personal fees and non-financial support from Pfizer-BMS and Csl-Behring.

Dr. Antz reports personal fees from Bayer, Boehringer Ingelheim, Daiichi Sankyo, personal fees from Pfizer, Sanofi Aventis, Medtronic, Biosense Webster, Novartis, Abbott, and Biotronik

Lien Desteghe has no conflict of interest to disclose.

Dr. Haeusler reports personal fees from Bayer, Boehringer-Ingelheim, Pfizer, Bristol-Myers Squibb, Daiichi Sankyo, Medtronic, Edwards Lifesciences, Sanofi, EIP Pharma, non-financial support from Getemed AG, and grants from Bayer.

Dr. Oldgren reports fees to his institution from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daichii-Sankyo, Pfizer, and Sanofi.

Dr. Reinecke reports personal fees from BMS, MedUpdate, NephroUpdate, Pfizer, and Pluristem; and grants from the German Federal Ministry for Education and Research (BMBF), Bard, Bayer, and Biotronik.

Dr. Roldán has received consultant and / or speaker fees from Bayer Healthcare, Boehringer-Ingelheim, Bristol-Myers Squibb, Leo Pharma, Pfizer and Rovi .

Dr. Rowell: None declared

Dr. Sinnaeve: None declared

Dr. Collins reports personal fees from Daichii Sankyo, Pfizer, Bayer and Boehringer Ingelheim.

John Camm has received institutional research grants and personal fees for advice and for speaking from Bayer, Boehringer Ingelheim, Daiichi Sankyo and Pfizer/BMS.

Dr. Heidbuchel reports personal fees before June 2017 from Abbott, Pfizer/BMS, Daiichi-Sankyo, Boehringer-Ingelheim, Cardiome; he receives grants from Bayer, Bracco Imaging Europe, Medtronic, and St. Jude Medical through the Universities of Hasselt and Antwerp, Belgium.

**References:**

1. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm A. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;**15**(5):625-51.

2. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, Advisors. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;**Oct;17(10)**:1467-507.

3. Kotecha D, Breithardt G, Camm AJ, Lip GYH, Schotten U, Ahlsson A, Arnar D, Atar D, Auricchio A, Bax J, Benussi S, Blomstrom-Lundqvist C, Borggrefe M, Boriani G, Brandes A, Calkins H, Casadei B, Castella M, Chua W, Crijns H, Dobrev D, Fabritz L, Feuring M, Freedman B, Gerth A, Goette A, Guasch E, Haase D, Hatem S, Haeusler KG, Heidbuchel H, Hendriks J, Hunter C, Kaab S, Kespohl S, Landmesser U, Lane DA, Lewalter T, Mont L, Nabauer M, Nielsen JC, Oeff M, Oldgren J, Oto A, Pison L, Potpara T, Ravens U, Richard-Lordereau I, Rienstra M, Savelieva I, Schnabel R, Sinner MF, Sommer P, Themistoclakis S, Van Gelder IC, Vardas PE, Verma A, Wakili R, Weber E, Werring D, Willems S, Ziegler A, Hindricks G, Kirchhof P. Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. Europace 2018;**Epub ahead of print**.

4. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;**37**(38):2893-2962.

5. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Munoz DR, Rosenhek R, Sjogren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL, Group ESCSD. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017;**38**(36):2739-2791.

6. Lip GYH, Collet JP, Caterina R, Fauchier L, Lane DA, Larsen TB, Marin F, Morais J, Narasimhan C, Olshansky B, Pierard L, Potpara T, Sarrafzadegan N, Sliwa K, Varela G, Vilahur G, Weiss T, Boriani G, Rocca B, Group ESCSD. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace 2017;**19**(11):1757-1758.

7. De Caterina R, John Camm A. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. Europace 2016;**18**(1):6-11.

8. Steffel J, Atar D. Non-vitamin K oral anticoagulants in 'valvular' atrial fibrillation: a call for action. Europace 2016;**18**(1):1-3.

9. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB, Alexander JH. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation 2015;**132**(8):624-32.

10. Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, Clemens A, Reilly PA, Connolly SJ, Yusuf S, Wallentin L. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation 2016;**134**(8):589-98.

11. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Committee RAS, Investigators. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 2014;**35**(47):3377-85.

12. De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, Ruff CT, Antman EM, Braunwald E, Giugliano RP. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. J Am Coll Cardiol 2017;**69**(11):1372-1382.

13. Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee M. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2017;**6**(7):e005835.

14. Renda G, Ricci F, Giugliano RP, De Caterina R. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. J Am Coll Cardiol 2017;**69**(11):1363-1371.

15. Noseworthy PA, Yao X, Shah ND, Gersh BJ. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease. Int J Cardiol 2016;**209**:181-3.

16. Noseworthy PA, Yao X, Shah ND, Gersh BJ. Stroke and Bleeding Risks in NOAC- and Warfarin-Treated Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation. J Am Coll Cardiol 2016;**67**(25):3020-1.

17. Dominguez F, Climent V, Zorio E, Ripoll-Vera T, Salazar-Mendiguchia J, Garcia-Pinilla JM, Urbano-Moral JA, Fernandez-Fernandez X, Lopez-Cuenca D, Ajo-Ferrer R, Sanz-Sanchez J, Gomez-Perez Y, Lopez-Garrido MA, Barriales-Villa R, Gimeno JR, Garcia-Pavia P. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. Int J Cardiol 2017;**248**:232-238.

18. Ruiz Ortiz M, Muniz J, Rana Miguez P, Roldan I, Marin F, Esteve-Pastor MA, Cequier A, Martinez-Selles M, Bertomeu V, Anguita M. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace 2017;**Epub ahead of print**.

19. Camm AJ, Fox KAA, Peterson E. Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. Europace 2018;**20**(1):1-11.

20. Huisman MV, Ma CS, Diener HC, Dubner SJ, Halperin JL, Rothman KJ, Teutsch C, Schoof N, Kleine E, Bartels DB, Lip GY, Investigators G-A. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Europace 2016;**18**(9):1308-18.

21. Fosbol EL, Vinding NE, Lamberts M, Staerk L, Gundlund A, Gadsboll K, Kober L, Gislason GH, Olesen JB. Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation. Europace 2017;**Epub ahead of print**.

22. Heidbuchel H, Vrijens B. Non-vitamin K antagonist oral anticoagulants (NOAC): considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace 2015;**17**(8):1317-8.

23. Lip GY, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost 2016;**14**(9):1711-4.

24. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014;**129**(9):961-70.

25. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;**32**(19):2387-94.

26. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;**33**(22):2821-30.

27. Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation 2016;**134**(1):24-36.

28. Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Hanna M, Keltai M, Parkhomenko A, Lopez-Sendon JL, Lopes RD, Siegbahn A, Granger CB, Wallentin L. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol 2016;**1**(4):451-60.

29. Fordyce CB, Hellkamp AS, Lokhnygina Y, Lindner SM, Piccini JP, Becker RC, Berkowitz SD, Breithardt G, Fox KA, Mahaffey KW, Nessel CC, Singer DE, Patel MR. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Circulation 2016;**134**(1):37-47.

30. Steffel J, Hindricks G. Apixaban in renal insufficiency: successful navigation between the Scylla and Charybdis. Eur Heart J 2012;**33**(22):2766-8.

31. Reinecke H, Brand E, Mesters R, Schabitz WR, Fisher M, Pavenstadt H, Breithardt G. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009;**20**(4):705-11.

32. Reinecke H, Engelbertz C, Schabitz WR. Preventing stroke in patients with chronic kidney disease and atrial fibrillation: benefit and risks of old and new oral anticoagulants. Stroke 2013;**44**(10):2935-41.

33. Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011;**80**(6):572-86.

34. Efird LM, Mishkin DS, Berlowitz DR, Ash AS, Hylek EM, Ozonoff A, Reisman JI, Zhao S, Jasuja GK, Rose AJ. Stratifying the risks of oral anticoagulation in patients with liver disease. Circ Cardiovasc Qual Outcomes 2014;**7**(3):461-7.

35. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;**361**(12):1139-51.

36. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011;**365**(10):883-91.

37. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011;**365**(11):981-92.

38. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2013;**386**(22):2093-104.

39. Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, Mueck W. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2013;**76**(1):89-98.

40. Douxfils J, Ageno W, Samama CM, Lessire S, Ten Cate H, Verhamme P, Dogne JM, Mullier F. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 2017;**Epub ahead of print**.

41. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogne JM. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012;**130**(6):956-66.

42. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thrombosis and Haemostasis 2012;**107**(5):985-97.

43. Pollack CV, Jr., Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med 2017;**377**(5):431-441.

44. Connolly SJ, Milling TJ, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M, Investigators A-. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med 2016;**375**(12):1131-41.

45. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ, Costin JC. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014;**371**(22):2141-2.

46. Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, Michalski F, Kohler C, Werth S, Sahin K, Tittl L, Hansel U, Weiss N. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014;**124**(6):955-62.

47. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messe SR, Pollack CV, Jr., Rodriguez F, Sarode R, Siegal D, Wiggins BS. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2017;**70**(24):3042-3067.

48. Douketis JD, Spyropoulos AC, Anderson JM, Arnold DM, Bates SM, Blostein M, Carrier M, Caprini JA, Clark NP, Coppens M, Dentali F, Duncan J, Gross PL, Kassis J, Kowalski S, Lee AY, Le Gal G, Le Templier G, Li N, MacKay E, Shah V, Shivakumar S, Solymoss S, Spencer FA, Syed S, Tafur AJ, Vanassche T, Thiele T, Wu C, Yeo E, Schulman S. The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. Thromb Haemost 2017;**117**(12):2415-2424.

49. Deharo JC, Sciaraffia E, Leclercq C, Amara W, Doering M, Bongiorni MG, Chen J, Dagres N, Estner H, Larsen TB, Johansen JB, Potpara TS, Proclemer A, Pison L, Brunet C, Blomstrom-Lundqvist C, Coordinated by the Scientific Initiatives Committee of the European Heart Rhythm A. Perioperative management of antithrombotic treatment during implantation or revision of cardiac implantable electronic devices: the European Snapshot Survey on Procedural Routines for Electronic Device Implantation (ESS-PREDI). Europace 2016;**18**(5):778-84.

50. Sticherling C, Marin F, Birnie D, Boriani G, Calkins H, Dan GA, Gulizia M, Halvorsen S, Hindricks G, Kuck KH, Moya A, Potpara T, Roldan V, Tilz R, Lip GY. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace 2015;**17**(8):1197-214.

51. Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, Okumura K, Serota H, Nordaby M, Guiver K, Biss B, Brouwer MA, Grimaldi M. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Engl J Med 2017;**376**(17):1627-36.

52. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, Ma CS, Hess S, Wells DS, Juang G, Vijgen J, Hugl BJ, Balasubramaniam R, De Chillou C, Davies DW, Fields LE, Natale A, Investigators V-A. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015;**36**(28):1805-11.

53. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Nielsen JC, Curtis AB, Davies DW, Day JD, d'Avila A, de Groot N, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Europace 2018;**20**(1):157-208.

54. Di Biase L, Callans D, Haeusler KG, Hindricks G, Al-Khalidi H, Mont L, Cosedis Nielsen J, Piccini JP, Schotten U, Kirchhof P. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. Europace 2017;**19**(1):132-138.

55. Potpara TS, Larsen TB, Deharo JC, Rossvoll O, Dagres N, Todd D, Pison L, Proclemer A, Purefellner H, Blomstrom-Lundqvist C, Scientific Initiatives Committee of European Heart Rhythm A. Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA). Europace 2015;**17**(6):986-93.

56. Death NCEiPOa. *The NCEPOD Classification of Intervention*. <http://www.ncepod.org.uk/classification.html>.

57. Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI, Anticoagulation SoCo. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 2016;**14**(3):623-7.

58. Albaladejo P, Bonhomme F, Blais N, Collet JP, Faraoni D, Fontana P, Godier A, Llau J, Longrois D, Marret E, Mismetti P, Rosencher N, Roullet S, Samama CM, Schved JF, Sie P, Steib A, Susen S, French Working Group on Perioperative H. Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) - September 2015. Anaesth Crit Care Pain Med 2017;**36**(1):73-76.

59. Beyer-Westendorf J, Gelbricht V, Forster K, Ebertz F, Kohler C, Werth S, Kuhlisch E, Stange T, Thieme C, Daschkow K, Weiss N. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014;**35**(28):1888-96.

60. Majeed A, Agren A, Holmstrom M, Bruzelius M, Chaireti R, Odeberg J, Hempel EL, Magnusson M, Frisk T, Schulman S. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 2017;**130**(15):1706-1712.

61. Gwyn JCV, Thomas MR, Kirchhof P. Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a viewpoint. Eur Heart J Cardiovasc Pharmacother 2017;**3**(3):157-162.

62. Lopes RD, Li L, Granger CB, Wang TY, Foody JM, Funk M, Peterson ED, Alexander KP. Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. Am J Med 2012;**125**(9):897-905.

63. Piccini JP, Jones WS. Triple Therapy for Atrial Fibrillation after PCI. New England Journal of Medicine 2017;**377**(16):1580-1582.

64. Vranckx P, Lewalter T, Valgimigli M, Tijssen JG, Reimitz P-E, Eckardt L, Lanz H-J, Zierhut W, Smolnik R, Goette A. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. American Heart Journal;**196**:105-112.

65. Alexander JH, Lopes RD, Thomas L, Alings M, Atar D, Aylward P, Goto S, Hanna M, Huber K, Husted S, Lewis BS, McMurray JJ, Pais P, Pouleur H, Steg PG, Verheugt FW, Wojdyla DM, Granger CB, Wallentin L. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2014;**35**(4):224-32.

66. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013;**127**(5):634-40.

67. Xu H, Ruff CT, Giugliano RP, Murphy SA, Nordio F, Patel I, Shi M, Mercuri M, Antman EM, Braunwald E. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. J Am Heart Assoc 2016;**5**(2):e002587.

68. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;**39**(3):123-260.

69. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr., Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW, Members AATF. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;**130**(23):e199-267.

70. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, Hohnloser SH, Investigators XV. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014;**35**(47):3346-55.

71. Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GY. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016;**388**(10055):1995-2003.

72. Itainen S, Lehto M, Vasankari T, Mustonen P, Kotamaki M, Numminen A, Lahtela H, Bah A, Hartikainen J, Hekkala AM, Airaksinen JKE. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion. Europace 2017;**Epub ahead of print**.

73. Frederiksen AS, Albertsen AE, Christesen AMS, Vinter N, Frost L, Moller DS. Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin. Europace 2017;**Epub ahead of print**.

74. Johansson AK, Juhlin T, Engdahl J, Lind S, Hagwall K, Rorsman C, Fodor E, Alenholt A, Paul Nordin A, Rosenqvist M, Frick M. Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism? Europace 2015;**17**(10):1514-7.

75. Tse DM, Young L, Ranta A, Barber PA. Intravenous alteplase and endovascular clot retrieval following reversal of dabigatran with idarucizumab. J Neurol Neurosurg Psychiatry 2017;**Epub ahead of print**.

76. Kermer P, Eschenfelder CC, Diener HC, Grond M, Abdalla Y, Althaus K, Berrouschot J, Cangur H, Daffertshofer M, Edelbusch S, Groschel K, Haase CG, Harloff A, Held V, Kauert A, Kraft P, Lenz A, Mullges W, Obermann M, Partowi S, Purrucker J, Ringleb PA, Rother J, Rossi R, Schafer N, Schneider A, Schuppner R, Seitz RJ, Szabo K, Wruck R. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection. Int J Stroke 2017;**12**(4):383-391.

77. Dietzel J, Piper SK, Ruschmann R, Wollboldt C, Usnich T, Hellwig S, Galinovic I, Audebert HJ, Endres M, Villringer K, Fiebach JB, Haeusler KG. Impact of pre-admission oral anticoagulation on ischaemic stroke volume, lesion pattern, and frequency of intracranial arterial occlusion in patients with atrial fibrillation. Europace 2017;**Epub ahead of print**.

78. Drouet L, Bal Dit Sollier C, Steiner T, Purrucker J. Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used? Int J Stroke 2016;**11**(7):748-58.

79. Seiffge DJ, Traenka C, Polymeris AA, Thilemann S, Wagner B, Hert L, Muller MD, Gensicke H, Peters N, Nickel CH, Stippich C, Sutter R, Marsch S, Fisch U, Guzman R, De Marchis GM, Lyrer PA, Bonati LH, Tsakiris DA, Engelter ST. Intravenous Thrombolysis in Patients with Stroke Taking Rivaroxaban Using Drug Specific Plasma Levels: Experience with a Standard Operation Procedure in Clinical Practice. J Stroke 2017;**19**(3):347-355.

80. Xian Y, Federspiel JJ, Hernandez AF, Laskowitz DT, Schwamm LH, Bhatt DL, Smith EE, Fonarow GC, Peterson ED. Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke. Circulation 2017;**135**(11):1024-1035.

81. Saver JL, Goyal M, van der Lugt A, Menon BK, Majoie CB, Dippel DW, Campbell BC, Nogueira RG, Demchuk AM, Tomasello A, Cardona P, Devlin TG, Frei DF, du Mesnil de Rochemont R, Berkhemer OA, Jovin TG, Siddiqui AH, van Zwam WH, Davis SM, Castano C, Sapkota BL, Fransen PS, Molina C, van Oostenbrugge RJ, Chamorro A, Lingsma H, Silver FL, Donnan GA, Shuaib A, Brown S, Stouch B, Mitchell PJ, Davalos A, Roos YB, Hill MD, Collaborators H. Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke: A Meta-analysis. Jama 2016;**316**(12):1279-88.

82. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, Yavagal DR, Ribo M, Cognard C, Hanel RA, Sila CA, Hassan AE, Millan M, Levy EI, Mitchell P, Chen M, English JD, Shah QA, Silver FL, Pereira VM, Mehta BP, Baxter BW, Abraham MG, Cardona P, Veznedaroglu E, Hellinger FR, Feng L, Kirmani JF, Lopes DK, Jankowitz BT, Frankel MR, Costalat V, Vora NA, Yoo AJ, Malik AM, Furlan AJ, Rubiera M, Aghaebrahim A, Olivot JM, Tekle WG, Shields R, Graves T, Lewis RJ, Smith WS, Liebeskind DS, Saver JL, Jovin TG. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med 2018;**378**(1):11-21.

83. Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, McTaggart RA, Torbey MT, Kim-Tenser M, Leslie-Mazwi T, Sarraj A, Kasner SE, Ansari SA, Yeatts SD, Hamilton S, Mlynash M, Heit JJ, Zaharchuk G, Kim S, Carrozzella J, Palesch YY, Demchuk AM, Bammer R, Lavori PW, Broderick JP, Lansberg MG, Investigators D. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med 2018;**Epub ahead of print**.

84. Wahlgren N, Moreira T, Michel P, Steiner T, Jansen O, Cognard C, Mattle HP, van Zwam W, Holmin S, Tatlisumak T, Petersson J, Caso V, Hacke W, Mazighi M, Arnold M, Fischer U, Szikora I, Pierot L, Fiehler J, Gralla J, Fazekas F, Lees KR, Eso-Ksu EEE, Ean. Mechanical thrombectomy in acute ischemic stroke: Consensus statement by ESO-Karolinska Stroke Update 2014/2015, supported by ESO, ESMINT, ESNR and EAN. Int J Stroke 2016;**11**(1):134-47.

85. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL, American Heart Association Stroke C. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2018;**Epub ahead of print**.

86. Paciaroni M, Agnelli G, Falocci N, Tsivgoulis G, Vadikolias K, Liantinioti C, Chondrogianni M, Bovi P, Carletti M, Cappellari M, Zedde M, Ntaios G, Karagkiozi E, Athanasakis G, Makaritsis K, Silvestrelli G, Lanari A, Ciccone A, Putaala J, Tomppo L, Tatlisumak T, Abdul-Rahim AH, Lees KR, Alberti A, Venti M, Acciarresi M, D'Amore C, Becattini C, Mosconi MG, Cimini LA, Soloperto R, Masotti L, Vannucchi V, Lorenzini G, Tassi R, Guideri F, Acampa M, Martini G, Sohn SI, Marcheselli S, Mumoli N, De Lodovici ML, Bono G, Furie KL, Tadi P, Yaghi S, Toni D, Letteri F, Tassinari T, Kargiotis O, Lotti EM, Flomin Y, Mancuso M, Maccarrone M, Giannini N, Bandini F, Pezzini A, Poli L, Padovani A, Scoditti U, Denti L, Consoli D, Galati F, Sacco S, Carolei A, Tiseo C, Gourbali V, Orlandi G, Giuntini M, Chiti A, Giorli E, Gialdini G, Corea F, Ageno W, Bellesini M, Colombo G, Monaco S, Maimone Baronello M, Karapanayiotides T, Caso V. Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study. J Am Heart Assoc 2017;**6**(12):e007034.

87. Ahmed N, Steiner T, Caso V, Wahlgren N. Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13–15 November 2016. European Stroke Journal 2017;**2**(2):95-102.

88. Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S, Rueckert C, Pezzini A, Poli L, Padovani A, Csiba L, Szabo L, Sohn SI, Tassinari T, Abdul-Rahim AH, Michel P, Cordier M, Vanacker P, Remillard S, Alberti A, Venti M, Scoditti U, Denti L, Orlandi G, Chiti A, Gialdini G, Bovi P, Carletti M, Rigatelli A, Putaala J, Tatlisumak T, Masotti L, Lorenzini G, Tassi R, Guideri F, Martini G, Tsivgoulis G, Vadikolias K, Liantinioti C, Corea F, Del Sette M, Ageno W, De Lodovici ML, Bono G, Baldi A, D'Anna S, Sacco S, Carolei A, Tiseo C, Acciarresi M, D'Amore C, Imberti D, Zabzuni D, Doronin B, Volodina V, Consoli D, Galati F, Pieroni A, Toni D, Monaco S, Baronello MM, Barlinn K, Pallesen LP, Kepplinger J, Bodechtel U, Gerber J, Deleu D, Melikyan G, Ibrahim F, Akhtar N, Mosconi MG, Bubba V, Silvestri I, Lees KR. Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study. Stroke 2015;**46**(8):2175-82.

89. Hankey GJ. Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned? Curr Cardiol Rep 2014;**16**(5):480.

90. Hemphill JC, 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, Scott PA, Selim MH, Woo D, American Heart Association Stroke C, Council on C, Stroke N, Council on Clinical C. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2015;**46**(7):2032-60.

91. Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, Flechsenhar J, Neugebauer H, Juttler E, Grau A, Palm F, Rother J, Michels P, Hamann GF, Huwel J, Hagemann G, Barber B, Terborg C, Trostdorf F, Bazner H, Roth A, Wohrle J, Keller M, Schwarz M, Reimann G, Volkmann J, Mullges W, Kraft P, Classen J, Hobohm C, Horn M, Milewski A, Reichmann H, Schneider H, Schimmel E, Fink GR, Dohmen C, Stetefeld H, Witte O, Gunther A, Neumann-Haefelin T, Racs AE, Nueckel M, Erbguth F, Kloska SP, Dorfler A, Kohrmann M, Schwab S, Huttner HB. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015;**313**(8):824-36.

92. Bronnum Nielsen P, Larsen TB, Gorst-Rasmussen A, Skjoth F, Rasmussen LH, Lip GY. Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study. Chest 2015;**147**(6):1651-8.

93. Korompoki E, Filippidis FT, Nielsen PB, Del Giudice A, Lip GYH, Kuramatsu JB, Huttner HB, Fang J, Schulman S, Marti-Fabregas J, Gathier CS, Viswanathan A, Biffi A, Poli D, Weimar C, Malzahn U, Heuschmann P, Veltkamp R. Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. Neurology 2017;**89**(7):687-96.

94. Nishimura M, Sab S, Reeves RR, Hsu JC. Percutaneous left atrial appendage occlusion in atrial fibrillation patients with a contraindication to oral anticoagulation: a focused review. Europace 2017;**Epub ahead of print**.

95. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;**383**(9921):955-62.

96. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;**123**(21):2363-72.

97. Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, Nordio F, Murphy SA, Kimura T, Jin J, Lanz H, Mercuri M, Braunwald E, Antman EM. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc 2016;**5**(5):e003432.

98. Hylek EM, D'Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006;**37**(4):1075-80.

99. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999;**159**(7):677-85.

100. Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, Aylward P, White H, Zamorano JL, Antman EM, Ruff CT. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. J Am Coll Cardiol 2016;**68**(11):1169-78.

101. Rao MP, Vinereanu D, Wojdyla DM, Alexander JH, Atar D, Hylek EM, Hanna M, Wallentin L, Lopes RD, Gersh BJ, Granger CB, Apixaban for Reduction in S, Other Thromboembolic Events in Atrial Fibrillation I. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am J Med 2017;**Epub ahead of print**.

102. Hanon O, Assayag P, Belmin J, Collet JP, Emeriau JP, Fauchier L, Forette F, Friocourt P, Gentric A, Leclercq C, Komajda M, Le Heuzey JY, French Society of G, Gerantology, French Society of C. Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. Archives of cardiovascular diseases 2013;**106**(5):303-23.

103. Sherrington C, Whitney JC, Lord SR, Herbert RD, Cumming RG, Close JC. Effective exercise for the prevention of falls: a systematic review and meta-analysis. J Am Geriatr Soc 2008;**56**(12):2234-43.

104. Tricco AC, Thomas SM, Veroniki AA, Hamid JS, Cogo E, Strifler L, Khan PA, Robson R, Sibley KM, MacDonald H, Riva JJ, Thavorn K, Wilson C, Holroyd-Leduc J, Kerr GD, Feldman F, Majumdar SR, Jaglal SB, Hui W, Straus SE. Comparisons of Interventions for Preventing Falls in Older Adults: A Systematic Review and Meta-analysis. Jama 2017;**318**(17):1687-1699.

105. Fumagalli S, Potpara TS, Bjerregaard Larsen T, Haugaa KH, Dobreanu D, Proclemer A, Dagres N. Frailty syndrome: an emerging clinical problem in the everyday management of clinical arrhythmias. The results of the European Heart Rhythm Association survey. Europace 2017;**19**(11):1896-1902.

106. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;**64**(3):292-303.

107. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clinical pharmacokinetics 2008;**47**(1):47-59.

108. Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. Journal of thrombosis and haemostasis : JTH 2011;**9**(11):2168-75.

109. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007;**47**(2):218-26.

110. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clinical pharmacokinetics 2011;**50**(10):675-86.

111. Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, LaCreta FP, Frost CE. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 2013;**76**(6):908-16.

112. Yin OQ, Tetsuya K, Miller R. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation. Eur J Clin Pharmacol 2014;**70**(11):1339-51.

113. Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 2016;**14**(6):1308-13.

114. Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 2016;**41**(1):206-32.

115. Breuer L, Ringwald J, Schwab S, Kohrmann M. Ischemic stroke in an obese patient receiving dabigatran. N Engl J Med 2013;**368**(25):2440-2.

116. Safouris A, Demulder A, Triantafyllou N, Tsivgoulis G. Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient. J Neurol Sci 2014;**346**(1-2):366-7.

117. Sandhu RK, Ezekowitz J, Andersson U, Alexander JH, Granger CB, Halvorsen S, Hanna M, Hijazi Z, Jansky P, Lopes RD, Wallentin L. The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J 2016;**37**(38):2869-78.

118. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI, Investigators A. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;**369**(9):799-808.

119. Balla SR, Cyr DD, Lokhnygina Y, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). Am J Cardiol 2017;**119**(12):1989-1996.

120. Braekkan SK, van der Graaf Y, Visseren FL, Algra A. Obesity and risk of bleeding: the SMART study. J Thromb Haemost 2016;**14**(1):65-72.

121. Van Eijkeren MA, Christiaens GC, Sixma JJ, Haspels AA. Menorrhagia: a review. Obstet Gynecol Surv 1989;**44**(6):421-9.

122. Huq FY, Tvarkova K, Arafa A, Kadir RA. Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation. Contraception 2011;**84**(2):128-32.

123. Stollberger C, Finsterer J. Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy Res 2016;**126**:98-101.

124. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Buller HR, Hokusai VTECI. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 2017;**Epub ahead of print**.

125. Posch F, Konigsbrugge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 2015;**136**(3):582-9.

126. Brunetti ND, Gesuete E, De Gennaro L, Correale M, Caldarola P, Gaglione A, Di Biase M. Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: A meta-analysis study. Int J Cardiol 2017;**230**:214-221.

127. Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist 2014;**19**(1):82-93.

128. Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005;**91**(4):472-7.

129. Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S, Kabali C, Reilly PA, Ezekowitz MD, Connolly SJ. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 2012;**126**(19):2309-16.

130. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ, investigators R-L. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;**376**(9745):975-83.

131. Fitzmaurice DA, Hobbs FD, Murray ET, Holder RL, Allan TF, Rose PE. Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial. Arch Intern Med 2000;**160**(15):2343-8.

132. Wilson SJ, Wells PS, Kovacs MJ, Lewis GM, Martin J, Burton E, Anderson DR. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. Cmaj 2003;**169**(4):293-8.

133. Heneghan CJ, Garcia-Alamino JM, Spencer EA, Ward AM, Perera R, Bankhead C, Alonso-Coello P, Fitzmaurice D, Mahtani KR, Onakpoya IJ. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev 2016;**7**:CD003839.